Full-Time

Senior Statistical Analyst

Posted on 1/12/2026

Deadline 1/12/27
American Heart Association

American Heart Association

5,001-10,000 employees

Compensation Overview

$105k - $125k/yr

Dallas, TX, USA

Remote

Category
Data & Analytics (2)
,
Required Skills
LLM
Python
R
Machine Learning
SAP Products
Data Analysis
Requirements
  • A Master’s or PhD degree in biostatistics, data science, biomedical informatics, computer science, epidemiology, public health, applied mathematics, engineering, or a related field
  • Minimum of five (5) years of experience in statistical analysis and modeling
  • A minimum of five (5) years of hands-on experience in either R or Python programming language
  • Clinical domain expertise: Three (3) or more years of experience analyzing patient clinical data (EHR, claims data, or clinical registries)
  • Deep expertise in advanced statistical methods, machine learning, artificial intelligence, and large language models
  • Proven experience handling large-scale, complex datasets and ensuring data quality/integrity
  • Demonstrated expertise in developing and executing Statistical Analysis Plans (SAPs)
  • Exceptional written and verbal communication skills, with the ability to explain complex analytic concepts to non-technical audiences
  • Strong project ownership and organizational skills, with a track record of managing multiple research timelines and priorities
  • A high level of self-motivation and the ability to work independently in a fast-paced, mission-driven environment
Responsibilities
  • Conducts advanced data analysis using real-world patient clinical or electronic health record data by employing statistical methods to address research questions related to cardiovascular disease and health disparities
  • Lead study design and develop, implement, and oversee Statistical Analysis Plans (SAPs), including robust predictive modeling and inference
  • Apply machine learning, artificial intelligence, and large language models to clinical datasets to uncover novel insights and improve analytic efficiency
  • Design, build, and maintain analytic code and pipelines to generate actionable insights and meet stakeholder and research requirements
  • Serve as a lead author or co-author, publishing research findings in high-impact scientific journals and presenting at major medical and data science conferences
  • Collaborate closely with clinicians and external PIs to refine research questions and translate clinical needs into technical specifications
  • Serve as a technical and topical expert, fostering collaboration, consulting, and acting as a liaison to Association stakeholders and external peers
  • Contribute to the development of communication strategies, including white papers, workshop planning, and publication roadmaps to highlight the impact of the Association’s data initiatives
Desired Qualifications
  • Cardiovascular Data Analysis expertise
  • Extensive experience in publishing research findings in high-impact journals
American Heart Association

American Heart Association

View

Company Size

5,001-10,000

Company Stage

Grant

Total Funding

$700K

Headquarters

Dallas, Texas

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • Heart Walk, Kids Heart Challenge rank top 5 U.S. fundraisers nationally.
  • Global expansion via CPR guidelines forums across MENA, India, Japan.
  • Corporate partnerships with Alnylam, Charles River accelerate research and awareness.

What critics are saying

  • Corporate sponsor dependence undermines independence; Alnylam partnership promotes proprietary drugs.
  • New dietary guidelines face backlash, eroding credibility with health professionals.
  • $20M Fontan program risks failure to deliver monitoring tools, damaging reputation.

What makes American Heart Association unique

  • Largest nonprofit cardiovascular research funder with 100+ year track record.
  • 35 million global volunteers amplify reach beyond traditional nonprofit scale.
  • Convenes multidisciplinary health systems for care coordination and quality improvement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

Employee Assistance Program

Wellness Program

Telemedicine

Tuition Reimbursement

Paid Vacation

Paid Holidays

Hybrid Work Options

Remote Work Options

Company News

Contract Pharma
Apr 10th, 2026
Charles River, American Heart Association partner to advance cardiovascular health awareness.

Charles River, American Heart Association partner to advance cardiovascular health awareness. Charles River to support the American Heart Association's Heart of Boston campaign, helping drive efforts to improve health outcomes across Greater Boston and the country. April 10, 2026 Associate Editor Charles River Laboratories International Inc. has partnered with the American Heart Association to support cardiovascular disease awareness, prevention, and community health initiatives. Through this collaboration, Charles River will support the American Heart Association's Heart of Boston campaign, helping drive efforts to improve health outcomes across Greater Boston and the country. "New data from the American Heart Association shows that cardiovascular disease continues to take an enormous toll on families and communities," said Kristen Eisenhauer, Chief Commercial Officer, Charles River. "We are proud to support the prevention, education, and science-driven efforts needed to help sustain progress and improve cardiovascular health worldwide." The joint effort comes at a critical time for public health. According to the American Heart Association's recently released 2026 Heart Disease and Stroke Statistics Update, heart disease remains the leading cause of death in the United States, while stroke is now the fourth-leading cause of death. Together, heart disease and stroke account for more than one in four U.S. deaths, despite recent improvements in overall cardiovascular mortality. While the latest data shows a decline in total cardiovascular deaths following years of increases associated with the COVID-19 pandemic, the American Heart Association's update underscores persistent risk factors across the population, including high rates of high blood pressure, diabetes, and obesity. These findings highlight the continued need for education, research, and public-private partnerships to advance long-term cardiovascular health. More Charles River news. Therna Biosciences, a biotechnology company pioneering programmable RNA therapeutics, recently joined forces with Charles River to advance single-patient RNA medicines for individuals with severe, ultra-rare disorders.

HealthTech HotSpot
Apr 9th, 2026
Charles River advances cardiovascular health awareness Through support of the American Heart Association.

Charles River advances cardiovascular health awareness Through support of the American Heart Association. WILMINGTON, Mass.-(BUSINESS WIRE)-$CRL #CDMO-Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with the American Heart Association, the world's leading nonprofit organization focused on heart and brain health, to support cardiovascular disease awareness, prevention, and community health initiatives. "New data from the American Heart Association shows that cardiovascular disease continues to take an enormous toll on families and communities," said Kristen Eisenhauer, Chief Commercial Officer, Charles River. "We are proud to support the prevention, education, and science-driven efforts needed to help sustain progress and improve cardiovascular health worldwide." Through this collaboration, Charles River will support the American Heart Association's Heart of Boston campaign, helping drive efforts to improve health outcomes across Greater Boston and the country. The support reinforces shared commitments to science-driven progress, prevention, and community engagement, and aligns with Charles River's corporate purpose - Together, HealthTech HotSpot LLC Create Healthier Lives - and its Corporate Citizenship strategy focused on advancing human health beyond the laboratory. The joint effort comes at a critical time for public health. According to the American Heart Association's recently released 2026 Heart Disease and Stroke Statistics Update, heart disease remains the leading cause of death in the United States, while stroke is now the fourth-leading cause of death. Together, heart disease and stroke account for more than one in four U.S. deaths, despite recent improvements in overall cardiovascular mortality. While the latest data shows a decline in total cardiovascular deaths following years of increases associated with the COVID-19 pandemic, the American Heart Association's update underscores persistent risk factors across the population, including high rates of high blood pressure, diabetes, and obesity. These findings highlight the continued need for education, research, and public-private partnerships to advance long-term cardiovascular health. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Its dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more, visit www.criver.com. Charles River Investor Contact: Todd Spencer Corporate Vice President, Investor Relations 781.222.6455 [email protected] Charles River Media Contact: Amy Cianciaruso Corporate Senior Vice President, Chief Communications Officer 781.222.6168 [email protected] April 10th, 2026 April 9th, 2026

Business Insider
Apr 7th, 2026
SimpliFed raises $10.8M Series A to expand virtual maternal health platform from lactation to full OB care

SimpliFed, a virtual maternal healthcare platform, has raised $10.8 million in an oversubscribed Series A round led by Morningside and Hesperia Capital. Foreground Capital and existing investors including AHA Social Impact Fund and Elizabeth Street Ventures participated. The company, which provides virtual breastfeeding and baby feeding support, is expanding into virtual OB services to offer prenatal and postpartum care for low-risk patients. SimpliFed connects families with certified lactation consultants and maternal health providers through telehealth visits, integrating with major electronic medical record systems. SimpliFed is on track to serve 5% of all US births in 2026 and is in network with major commercial health plans and Medicaid across several states. The funding will support growth of its Maternal Health Operating System and partnerships with health systems and OBGYN clinics.

American Heart Association
Mar 30th, 2026
New $20M effort aims to address critical gaps in care for people with single ventricle heart disease.

New $20M effort aims to address critical gaps in care for people with single ventricle heart disease. The American Heart Association and Additional Ventures develop program focused on improving long-term health for people living with Fontan circulation DALLAS, March 30, 2026 - The lifesaving surgery used to treat children with single ventricle heart disease, the Fontan procedure, can pose serious health complications throughout life. The American Heart Association, devoted to changing the future to a world of healthier lives for all and Additional Ventures, a research foundation working toward a cure for single ventricle heart disease, have committed a combined $20M to advance a coordinated, collaborative approach to improving the ability to predict, prevent and treat health complications in people living with Fontan circulation. Single ventricle heart disease affects about 6 in 10,0000 babies born in the US each year[1]. These children are born with only one working heart pump and must rely on a surgically created circulation (the Fontan circulation) to reroute blood through the body. While lifesaving, this circulation places long-term strain on the body and can lead to progressive damage across multiple organs. Today, clinicians lack reliable ways to monitor Fontan health, making them unable to detect early signs of decline. As a result, many patients appear stable until they suddenly experience severe complications that can be fatal or severely impact quality of life. The program will bring together clinicians, researchers and patients to generate scientific and clinical insights and develop tools to better guide care for people living with Fontan circulation. The program combines the strength of the American Heart Association's research infrastructure, guideline development, data coordination and registry science with Additional Ventures' leadership in single ventricle strategy, deep scientific expertise and unparalleled network across the single ventricle heart disease ecosystem. "People with Fontan circulation often develop complications with other organs in the body including the liver, kidneys and lungs," said Mariell Jessup, M.D., FAHA, chief medical and science officer of the American Heart Association. "The coordination between our two organizations will generate data and insight that can help patients and clinicians better monitor their health and intervene earlier." "While lifesaving, Fontan circulation creates complex, lifelong health challenges for single ventricle heart disease patients that we still do not fully understand," said Kirstie Keller, PhD, chief executive officer of Additional Ventures. "Through this collaboration, we will work with researchers, clinicians and patients to generate the scientific insights and tools needed to predict, detect and manage complications earlier. By building these resources, we hope to enable a more proactive, science-informed approach to lifelong care for Fontan patients. The six-year, multi-phase strategy begins with evaluating current approaches to monitoring Fontan circulation patients; identifying gaps in care, data and infrastructure; and engaging patients, clinicians and scientists in program design and implementation. Ultimately, the goal is to establish the scientific foundation and clinical tools needed to move the field from reactive care to proactive health monitoring of patients with Fontan circulation, creating the infrastructure for a future standard of care. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1. About Additional Ventures Additional Ventures is a research foundation committed to curing single ventricle heart disease through transformative research and strategic investments that revolutionize treatment and care. By combining deep scientific expertise with strategic, flexible funding, Additional Ventures supports bold, collaborative research across the translational pipeline. Since its founding in 2020, Additional Ventures has committed more than $110 million to single ventricle heart disease research. Learn more about our work and progress in our most recent Impact Report, at additionalventures.org, or by following us on LinkedIn. For Media Inquiries: 214-706-1173 For Public Inquiries: 1-800-AHA-USA1 (242-8721)

CBS News
Mar 29th, 2026
New heart health dietary guidelines.

New heart health dietary guidelines. The American Heart Association has released new dietary guidelines on how to stay heart healthy to improve quality of life and save lives. Dr. Celine Gounder breaks down what to know. 4h ago Around the web. 60 minutes.

INACTIVE